| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
116,630,000 |
| Market
Cap: |
4.66(B) |
| Last
Volume: |
684,519 |
Avg
Vol: |
1,046,622 |
| 52
Week Range: |
$34.73 - $114.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. Co. has marketed Korlym (mifepristone) in the U.S. for the treatment of patients with Cushing's syndrome. Co.'s primary compounds have entered the clinic as potential treatments for serious disorders, including Cushing's syndrome, solid tumors (such as ovarian cancer, castration-resistant prostate cancer and adrenocortical cancer with cortisol excess), antipsychotic induced weight gain and non-alcoholic steatohepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
134,000 |
395,726 |
1,168,615 |
1,539,686 |
| Total Sell Value |
$9,029,574 |
$29,204,617 |
$94,205,221 |
$107,619,852 |
| Total People Sold |
4 |
6 |
7 |
7 |
| Total Sell Transactions |
8 |
24 |
69 |
110 |
| End Date |
2025-11-16 |
2025-08-15 |
2025-02-14 |
2024-02-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hunt Hazel |
Chief Scientific Officer |
• – – |
2026-02-09 |
4 |
D |
$41.31 |
$3,220,858 |
D/D |
(77,968) |
255,437 |
|
- |
|
| Hunt Hazel |
Chief Scientific Officer |
• – – |
2026-02-09 |
4 |
OE |
$3.88 |
$582,000 |
D/D |
150,000 |
333,405 |
|
- |
|
| Guyer William |
Chief Development Officer |
• – – |
2026-02-03 |
4 |
AS |
$40.87 |
$817,334 |
D/D |
(20,000) |
1,235 |
|
0% |
|
| Guyer William |
Chief Development Officer |
• – – |
2026-02-03 |
4 |
OE |
$21.65 |
$433,000 |
D/D |
20,000 |
21,235 |
|
- |
|
| Baker G Leonard Jr |
|
– • – |
2026-01-27 |
4 |
OE |
$5.86 |
$1,608,700 |
I/I |
140,000 |
1,095,262 |
|
- |
|
| Maduck Sean |
See Remarks |
• – – |
2026-01-08 |
4 |
A |
$0.00 |
$0 |
I/I |
54,570 |
34,000 |
|
- |
|
| Maduck Sean |
See Remarks |
• – – |
2026-01-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
54,570 |
5,147 |
|
- |
|
| Guyer William |
Chief Development Officer |
• – – |
2026-01-06 |
4 |
AS |
$35.18 |
$703,656 |
D/D |
(20,000) |
1,235 |
|
14% |
|
| Guyer William |
Chief Development Officer |
• – – |
2026-01-06 |
4 |
OE |
$21.65 |
$433,000 |
D/D |
20,000 |
21,235 |
|
- |
|
| Baker G Leonard Jr |
|
– • – |
2026-01-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
0 |
3,308,303 |
|
- |
|
| Belanoff Joseph K |
Chief Executive Officer |
• • – |
2025-12-24 |
4 |
A |
$0.00 |
$0 |
I/I |
243,154 |
2,944,524 |
|
- |
|
| Belanoff Joseph K |
Chief Executive Officer |
• • – |
2025-12-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
243,154 |
0 |
|
- |
|
| Belanoff Joseph K |
Chief Executive Officer |
• • – |
2025-12-24 |
4 |
D |
$83.59 |
$25,649,257 |
D/D |
(306,846) |
243,154 |
|
- |
|
| Belanoff Joseph K |
Chief Executive Officer |
• • – |
2025-12-24 |
4 |
OE |
$3.88 |
$2,134,000 |
D/D |
550,000 |
550,000 |
|
- |
|
| Robb Gary Charles |
Chief Business Officer |
• – – |
2025-12-24 |
4 |
D |
$83.59 |
$6,710,940 |
D/D |
(80,284) |
78,626 |
|
- |
|
| Robb Gary Charles |
Chief Business Officer |
• – – |
2025-12-24 |
4 |
OE |
$3.88 |
$562,600 |
D/D |
145,000 |
158,910 |
|
- |
|
| Wilson James N |
|
– • – |
2025-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
400,000 |
200,000 |
|
- |
|
| Wilson James N |
|
– • – |
2025-12-12 |
4 |
GD |
$0.00 |
$0 |
I/I |
400,000 |
1,045,168 |
|
- |
|
| Guyer William |
Chief Development Officer |
• – – |
2025-12-02 |
4 |
AS |
$80.05 |
$1,601,526 |
D/D |
(20,000) |
1,235 |
|
-49% |
|
| Guyer William |
Chief Development Officer |
• – – |
2025-12-02 |
4 |
OE |
$21.65 |
$433,000 |
D/D |
20,000 |
21,235 |
|
- |
|
| Guyer William |
Chief Development Officer |
• – – |
2025-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
787 |
1,235 |
|
- |
|
| Guyer William |
Chief Development Officer |
• – – |
2025-12-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
787 |
0 |
|
- |
|
| Maduck Sean |
See Remarks |
• – – |
2025-12-02 |
4 |
D |
$79.78 |
$10,770 |
D/D |
(135) |
8,179 |
|
- |
|
| Mokari Atabak |
Chief Financial Officer |
• – – |
2025-12-02 |
4 |
D |
$79.78 |
$9,414 |
D/D |
(118) |
14,559 |
|
- |
|
| Robb Gary Charles |
Chief Business Officer |
• – – |
2025-12-02 |
4 |
D |
$79.78 |
$11,807 |
D/D |
(148) |
13,910 |
|
- |
|
718 Records found
|
|
Page 1 of 29 |
|
|
1.63 (4.25%) 
